Pre-Conference Course on Basics of AI - 06 October 2026
Introduction to Artificial Intelligence (AI) and Machine Learning (ML)
- History of AI
- Types of AI
- Current situation and real-life examples
- Technological Basics
- Different learning / training Methods
- Example use cases
Data and Models
- Overview of core model architectures and data types
- Data splitting: training, validation, and testing phases
- Ensuring data quality, representativeness, and overcoming common bottlenecks
Specialised AI: How Task-Specific Models Work
- Specialized vs. General-Purpose AI: Understanding the key differences
- Step-by-step training process, using cancer diagnostics as a case study
- The roles of pre-training and fine-tuning
- Ensuring AI traceability and explainability in critical Tasks
General-Purpose AI: How Generative Models like GPT & Co. Work
- Fundamentals of Large Language Models (LLMs)
- Strengths and limitations of LLMs compared to specialized AI
- Introduction to LLMs acting as autonomous agent
Risk Management / Validation for AI/ML Solutions
- Applying ICH Q9 QRM to AI/ML
- QRM throughout the System Life Cycle
- Thinking critically about AI-enabled Computerized Systems
- Using the AI Maturity Model
- Achieving Data and Model Governance
Overview of AI/ML in Pharmaceuticals, Biotech and Medical Devices
- Challenges facing the life sciences industry in dealing with AI and ML
- GAMP® 5 meets AI: The GAMP AI Guide
- Use cases for AI in pharma and biotechGMLP (Good Machine Learning Practice): An SDLC for AI/ML
Annex 22 / AI Conference 2025 - 07-08 October 2026
Overview of AI in GxP: Capabilities & Opportunities
- General introduction
- Brief introduction to AI & ML
- Drivers for using AI & ML in pharma
- Regulations and guidance
AI Limitations and Areas of Concern
- Current situation
- What do you need to watch out for?
- What are the risks?
Current regulatory Situation – The Current Status in Regard to EU GMP Guide Annex 11 and Annex 22 - and Expectations in the Context of an Inspection
Panel Discussion
- Human in the loop requirements
- Supplier overview & collaboration
- Long-term sustainability
- Dynamic systems / continuous learning
- Do AI systems, particularly (autonomous) agent systems, require a paradigm shift in validation (Validation 4.0)?
Risks and Limitations of Large Language Models (LLMs): A Critical Discussion
- Open-Source vs. Closed-Source: Transparency, control, and dependencies
- Bias in training data and its impact on results
- Data privacy and confidentiality when using generative AI
- Hallucinations: Why LLMs generate convincingly false information
AI in the Pharmaceutical Industry: Regulations, Quality Assurance and Practice
- Regulatory requirements (EU AI Act, Annex 11, 22, Chapter 4, Part 11).
- AI governance: managing risks associated with non-GxP systems in a GxP environment.
- Validation: CSV as a holistic approach for compliant AI.
- Human-machine interaction: Human-in-the-loop vs. human-centric concept.
- Practical examples: Benefits of AI in quality assurance / Thoughts on the potential and risks of AI for patient care
- Outlook: The future role of AI agents.
AI in IT Quality Assurance: From Governance to Inspection Readiness in a GxP Environment
- Why QA cannot stay on the Side-lines?
- What makes AI different from traditional computerised systems?
- Practical quality challenges observed in projects
- Inspection readiness: what QA should already prepare for?
AI Strategy & AI Governance – The Big Picture
- What do organizations need to consider when approaching AI in GxP
- How does AI strategy interconnect within a typical corporate strategy layout?
- What governance functions are relevant and how do they integrate
- How can enabling elements like data, Quality, and technology be activated
From AI Hype to Trusted AI in GxP
- Why AI struggles in GxP environments: The reality behind hype, pilots, and Shadow AI
- Regulatory expectations for AI: Trust, validation, explainability, and compliance
- Building the foundations for trusted AI: Governance, data readiness, and organisational capabilities
- From foundations to governed AI: Practical frameworks and maturity models
- When AI becomes a GxP system: Validation, risk control, and leadership responsibilities
- Beyond traditional validation: Patient-facing LLMs, adversarial testing, and continuous validation
- Leadership takeaways: How organisations move from experimentation to trusted AI
GenAI Platform: A Technical and Compliant Approach for Complaint GenAI Usage in a GxP-Regulated Environment
- Platform mindset: Embracing a platform-oriented approach to leverage GenAI capabilities effectively.
- Democratization of Technology: Ensuring easy access to GenAI tools across the enter-prise, empowering end-users to innovate responsibly.
- Quality Risk Management: Implementing a comprehensive quality risk management framework to evaluate and mitigate potential quality impacts associated with GenAI usage.
AI-Based Assistance Software to Increase Production Efficiency in a GMP-Regulated Environment
- Maintenance Challenges
- How knowledge databases work
- Framework Conditions for the Use of the AI-Based Assistant
- Quality Control of Knowledge Entries
- Benefits, Impact, and Outlook
Security Implications of AI for Pharma Manufacturing
- Overview: State-of-the-art cyber security & resilience
- AI as a threat versus AI as an opportunity
- Examples AI-based attacks
- Urgent call to action for the industry
AI in Maintenance – Between Expectation and Reality
- Critical Reflection on AI in Maintenance
- Expectations and roadblocks
- Limits of data driven Models
- Pragmatic alternatives
- Practical experience at CSL
Digitalization/Automation as the Basis for the Efficient Use of AI in QA and QC
- Basics for QC & QA on IT framework - digitalization - automation - use of AI
- Generation of raw data and data systems
- Real-life automation examples and AI examples from QA & QC
GxP Compliant Guardrails in the Age of Reasoning Models and Agents
- Introduction to reasoning models
- Regulatory background in pharma
- Pharma Guardrails